Study guide

10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease

WHNP-BC Women's Health Nurse Practitioner Study Guide Exam

Track your progress as you read

Finished sections get a check mark.

1 Introduction: About the WHNP-BC Exam

WHNP-BC Exam Facts, Blueprint & Study Plan

2 Chapter 1: Well-Woman Care, Assessment & Gynecologic Screening

1.1 Well-Woman Health Maintenance & Routine Screening Across the Lifespan 1.2 Comprehensive Health History & Physical Examination (Female and Male) 1.3 Cervical Cancer Screening & ASCCP Risk-Based Management Guidelines 1.4 Breast Health Assessment, Diagnostic Imaging & Breast Cancer Screening

3 Chapter 2: Vulvovaginal Infections, STIs & HIV Prevention

2.1 Vulvovaginitis: Bacterial Vaginosis, Candidiasis & Trichomoniasis 2.2 Sexually Transmitted Infections: Chlamydia, Gonorrhea, Syphilis & Pelvic Inflammatory Disease 2.3 Viral STIs & Chronic Vulvar Dermatoses (HSV, HPV, Lichen Sclerosus & Lichen Planus) 2.4 HIV Prevention (PrEP & PEP), Viral Hepatitis, Mycoplasma genitalium & Ectoparasites

4 Chapter 3: Gynecologic Disorders, Pelvic Pain & Gynecologic Cancers

3.1 Abnormal Uterine Bleeding & the FIGO PALM-COEIN Classification 3.2 Uterine Leiomyomas, Adenomyosis & Endometrial and Cervical Polyps 3.3 Dysmenorrhea, Endometriosis & Chronic Pelvic Pain Management 3.4 Benign Pelvic Masses, Pelvic Organ Prolapse & Urinary Incontinence 3.5 Gynecologic Malignancies: Endometrial, Ovarian, Cervical, Vulvar & Vaginal Cancers

5 Chapter 4: Reproductive Physiology, Endocrinology & Infertility

4.1 Reproductive Anatomy, Puberty, the Menstrual Cycle & Müllerian Anomalies 4.2 Polycystic Ovary Syndrome (PCOS) & Hyperandrogenic Disorders 4.3 Amenorrhea Evaluation: Primary & Secondary Etiologies 4.4 Infertility Workup, Ovulation Induction & Assisted Reproductive Technologies

6 Chapter 5: Contraception, Family Planning & Unintended Pregnancy

5.1 Long-Acting Reversible Contraception (LARC): IUDs & Subdermal Implants 5.2 Hormonal Contraceptives: Combined & Progestin-Only Methods 5.3 Emergency Contraception, Barrier Methods & Fertility Awareness-Based Methods 5.4 CDC U.S. Medical Eligibility Criteria (US MEC) & Permanent Sterilization 5.5 Unintended Pregnancy: Options Counseling, Medication & Procedural Abortion

7 Chapter 6: Perimenopause, Menopause & Postmenopausal Health

6.1 Menopausal Transition Physiology, Vasomotor Symptoms & Clinical Staging (STRAW+10) 6.2 Menopausal Hormone Therapy (MHT): Indications, Regimens & Contraindications 6.3 Genitourinary Syndrome of Menopause (GSM) & Postmenopausal Osteoporosis

8 Chapter 7: Sexual Health, Male Reproductive Health & LGBTQ+ Care

7.1 Female Sexual Function, Sexual Dysfunction & LGBTQ+ Sexual Health 7.2 Male Sexual & Reproductive Health: STIs, Infertility, Contraception & Sexual Dysfunction

9 Chapter 8: Preconception, Fetal Development & Normal Antepartum Care

8.1 Preconception Counseling, Risk Assessment & Teratogen Exposure 8.2 Early Pregnancy Diagnosis, Gestational Dating & Initial Prenatal Evaluation 8.3 Embryonic & Fetal Development, the Placenta, Fetal Circulation & Amniotic Fluid 8.4 Routine Antepartum Surveillance, Nutritional Needs & Weight Gain Guidelines 8.5 Management of Common Discomforts & Physiologic Changes in Pregnancy

10 Chapter 9: Antepartum Complications I: Hypertension, Diabetes, Bleeding & Preterm Birth

9.1 Hypertensive Disorders of Pregnancy & Preeclampsia Management 9.2 Gestational Diabetes Mellitus: Screening, Glycemic Targets & Management 9.3 Bleeding in Pregnancy: Spontaneous Abortion, Ectopic Pregnancy & Placental Disorders 9.4 Preterm Labor, PPROM & Cervical Insufficiency

11 Chapter 10: Antepartum Complications II: Infections, Medical Disorders & Fetal Conditions

10.1 Infections in Pregnancy: CMV, Parvovirus, Varicella, Rubella, Toxoplasmosis, Listeria, GBS & HIV 10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease 10.3 Gestational Trophoblastic Disease, Recurrent Loss, Stillbirth & Perinatal Bereavement 10.4 Multiple Gestation, Fetal Growth Disorders, Amniotic Fluid Abnormalities, Malpresentation & Postterm Pregnancy 10.5 Rh(D) Alloimmunization & Hemolytic Disease of the Fetus and Newborn

12 Chapter 11: Intrapartum Principles & Fetal Surveillance

11.1 Electronic Fetal Monitoring (EFM): Baseline, Variability, Decelerations & Categories 11.2 Labor Assessment, Stages of Labor & Labor Dystocia 11.3 Trial of Labor After Cesarean (TOLAC) & Intrapartum Emergencies

13 Chapter 12: Postpartum Management, Lactation & Puerperal Complications

12.1 Postpartum Involution, Physical Recovery & Routine Puerperal Care 12.2 Postpartum Hemorrhage: The 4 Ts, Uterotonic Pharmacotherapy & Emergency Protocols 12.3 Puerperal Infections & Postpartum Mood Disorders 12.4 Physiology of Lactation, Common Breastfeeding Challenges & Infant Feeding 12.5 Other Puerperal Complications: Hematomas, Urinary Retention, Hemorrhoids, Postpartum Hypertension & Warning Signs

14 Chapter 13: Primary Care: Cardiovascular, Thromboembolic, Respiratory & HEENT Conditions

13.1 Hypertension & Cardiovascular Disease in Women: Gender-Specific Presentations 13.2 Dyslipidemia & ASCVD Risk: The 2026 ACC/AHA Guideline 13.3 Venous Thromboembolism in Women: Risk, Diagnosis, Treatment & Prevention in Pregnancy 13.4 Respiratory Conditions in Women: Asthma Management & Respiratory Infections 13.5 HEENT & Upper Respiratory Conditions: Conjunctivitis, Rhinitis, Pharyngitis, Sinusitis, Otitis & the Common Cold

15 Chapter 14: Primary Care: Endocrine, Metabolic & Gastrointestinal Disorders

14.1 Type 2 Diabetes Mellitus & Metabolic Syndrome in Women 14.2 Obesity, Weight Management & Healthy Lifestyle Counseling 14.3 Thyroid Disorders: Hypothyroidism, Hyperthyroidism & Postpartum Thyroiditis 14.4 Gastrointestinal Conditions: GERD, Irritable Bowel Syndrome & Gallbladder Disease 14.5 Constipation, Hemorrhoids, Peptic Ulcer Disease & Other Upper and Lower GI Disorders

16 Chapter 15: Primary Care: Renal, Hematologic, Rheumatologic, Musculoskeletal & Dermatologic Health

15.1 Urinary Tract Infections, Pyelonephritis, Hematuria & Nephrolithiasis 15.2 Anemias in Women: Iron Deficiency, Microcytic & Macrocytic Anemias 15.3 Autoimmune & Rheumatologic Conditions: SLE, Antiphospholipid Syndrome, RA & Fibromyalgia 15.4 Musculoskeletal Complaints: Low Back Pain, Osteoarthritis, Sprains, Strains & Common Conditions in Women 15.5 Common Dermatologic Disorders in Women Across the Lifespan 15.6 Common Skin Conditions: Eczema, Contact Dermatitis, Psoriasis, Tinea, Vitiligo, Skin Lesions & Hidradenitis

17 Chapter 16: Neurologic, Mental Health, Behavioral & Psychosocial Care

16.1 Headache Disorders in Women: Migraine, Tension-Type, Red Flags & Hormonal Considerations 16.2 Depressive Disorders & Anxiety in Women Across the Reproductive Lifespan 16.3 Substance Use Disorders: Alcohol, Nicotine, Cannabis & Opioid Use in Women 16.4 Intimate Partner Violence (IPV), Sexual Assault & Trauma-Informed Care

18 Chapter 17: Assessment, Diagnostic Testing & Interpretation

17.1 Laboratory Diagnostics: Hematology, Coagulation, Chemistry, Hormone, Serologic & Screening Tests 17.2 Genetic Principles: Inheritance Patterns, Carrier Screening & Hereditary Cancer Risk Assessment 17.3 Gynecologic Office Diagnostic Procedures: Wet Mounts, Endometrial Biopsy & Colposcopy 17.4 Obstetric Diagnostic Imaging & Genetic Screening Modalities

19 Chapter 18: Pharmacology: Pharmacokinetics, Pharmacodynamics, Pharmacogenetics & Safe Prescribing

18.1 Clinical Pharmacokinetics Across the Female Lifespan & the FDA PLLR 18.2 Pharmacodynamics, Pharmacogenetics & Clinically Important Drug Interactions in Women's Health 18.3 Antimicrobial Stewardship & Pharmacotherapy in Pregnancy and Lactation

20 Chapter 19: Professional Role, Legal, Ethical, Quality & Health Equity Responsibilities

19.1 APRN Scope of Practice, Consensus Model & Collaborative Practice 19.2 Legal, Ethical & Informed Consent Issues in Reproductive Health Care 19.3 Evidence-Based Practice, Research Terminology, Quality Improvement & Patient Safety 19.4 Maternal Health Equity, Cultural Humility & Gender-Affirming Gynecologic Care

10.2 Maternal Medical Disorders in Pregnancy: Pregestational Diabetes, Epilepsy, Thrombocytopenia, Obesity & Cardiac Disease

Key Takeaways Explain This Topic AI

In pregestational diabetes, congenital anomaly risk rises with the A1C at conception, so the preconception target is below 6.5%, and a fetal echocardiogram is recommended.

Well-controlled pregestational diabetes is delivered at 39 0/7–39 6/7 weeks; vascular complications or poor control move delivery to 36 0/7–38 6/7 weeks.

Lamotrigine and levetiracetam levels fall during pregnancy, so monitor drug levels, and prescribe at least 0.4 mg of folic acid daily (AAN/AES/SMFM 2024).

Gestational thrombocytopenia is the most common cause of low platelets in pregnancy, is usually above 100,000/mcL, appears late, and carries no fetal risk.

Peripartum cardiomyopathy is heart failure with an ejection fraction below 45% occurring late in pregnancy or within months postpartum; dyspnea and orthopnea should not be dismissed as normal pregnancy.

Last updated: October 2026

  • Pregestational (Type 1 or Type 2) Diabetes
  • Risks

Hyperglycemia during organogenesis causes congenital anomalies (cardiac defects, neural tube defects, and caudal regression syndrome), with risk rising steadily with the A1C at conception . Later risks include miscarriage, preeclampsia, macrosomia and shoulder dystocia, polyhydramnios, stillbirth, and neonatal hypoglycemia, hyperbilirubinemia, and respiratory distress.

Care Before and During Pregnancy

Preconception: A1C below 6.5% if achievable without hypoglycemia, folic acid, and a switch from teratogenic drugs (ACE inhibitors, ARBs, statins, GLP-1 receptor agonists).

Baseline assessment: Dilated retinal exam (retinopathy can progress during pregnancy, so repeat as advised), serum creatinine and urine albumin-to-creatinine ratio, TSH (especially in type 1 diabetes), and ECG when cardiovascular risk is present.

Aspirin 81 mg daily from 12–28 weeks for preeclampsia prevention.

Glycemic targets match those for gestational diabetes: fasting <95 mg/dL, 1-hour postprandial <140 mg/dL, 2-hour <120 mg/dL. Insulin is preferred. Insulin needs often fall in the first trimester (hypoglycemia risk, especially in type 1) and rise steeply in the second and third trimesters as placental hormones increase insulin resistance. Continuous glucose monitoring is recommended in type 1 diabetes.

DKA can develop at lower glucose levels in pregnancy and is dangerous for the fetus.

Fetal evaluation: Early dating ultrasound, a detailed anatomy scan, fetal echocardiography (about 22 weeks), growth scans, and antenatal testing from about 32 weeks.

Delivery timing (ACOG): 39 0/7–39 6/7 weeks if well controlled; 36 0/7–38 6/7 weeks with vascular complications, poor control, or prior stillbirth.

Postpartum: Insulin requirements drop sharply after the placenta delivers, so reduce doses immediately to avoid hypoglycemia; breastfeeding further lowers glucose.

Epilepsy

About one-third of patients have more seizures during pregnancy, often from falling drug levels , poor adherence driven by fear of teratogenicity, or sleep deprivation.

Valproate carries the highest risk of malformations (neural tube defects and others) and lower child IQ and should be avoided when possible; lamotrigine and levetiracetam have the lowest malformation rates.

Lamotrigine clearance rises by up to 200%–300% (estrogen-induced glucuronidation), and levetiracetam clearance also rises, so obtain a baseline level and check levels at least each trimester (often monthly) with dose adjustments. Reduce doses gradually after delivery to avoid toxicity.

Folic acid at least 0.4 mg daily before and throughout pregnancy (AAN/AES/SMFM 2024); higher doses are common but not proven better.

Breastfeeding is encouraged on most antiseizure drugs. Counsel safe infant-care practices, such as changing diapers on the floor and avoiding bathing the infant alone.

A new seizure after 20 weeks is eclampsia until proven otherwise : give magnesium sulfate and evaluate.

Thrombocytopenia in Pregnancy

Cause Typical Platelet Count and Timing Distinguishing Features Fetal Risk

Gestational thrombocytopenia (about 75% of cases) Usually >100,000/mcL (rarely <70,000); late second or third trimester No prior history; no other abnormalities; resolves within weeks postpartum None

Immune thrombocytopenia (ITP) Often <100,000/mcL; can occur early History of low platelets or bleeding; diagnosis of exclusion Maternal IgG can cause neonatal thrombocytopenia

Preeclampsia/HELLP Falls in the third trimester or postpartum Hypertension, elevated liver enzymes, hemolysis (LDH ≥600) Related to the underlying disease

TTP, HUS, acute fatty liver, DIC Variable, often severe Microangiopathic hemolysis, renal failure, neurologic signs, hypoglycemia, coagulopathy Severe

Treat ITP when platelets are below about 30,000/mcL , when there is bleeding, or before procedures, using corticosteroids or IVIG first-line. Many anesthesiologists accept neuraxial anesthesia at 70,000/mcL or higher (Society for Obstetric Anesthesia and Perinatology), and a count of about 50,000/mcL is generally adequate for cesarean birth.

Obesity (BMI 30 or Higher)

Maternal risks: Gestational diabetes, preeclampsia, VTE, cesarean birth, wound infection, anesthetic complications, and postpartum hemorrhage.

Fetal risks: Neural tube and cardiac anomalies, macrosomia, stillbirth , and reduced ultrasound visualization of anatomy.

Care: Early diabetes screening, aspirin when obesity coexists with another moderate preeclampsia risk factor, a weight gain target of 11–20 lb , an anesthesia consultation for severe obesity, and mechanical plus pharmacologic VTE prophylaxis after cesarean as indicated.

Antenatal testing (ACOG Committee Opinion 828): Weekly testing from 34 0/7 weeks for BMI ≥40 and from 37 0/7 weeks for BMI 35.0–39.9 .

After bariatric surgery: Delay pregnancy 12–18 months; monitor iron, B12, folate, vitamin D, and calcium; avoid the 50-g glucose challenge after Roux-en-Y gastric bypass (dumping syndrome) and use fingerstick monitoring instead; take abdominal pain seriously (internal hernia).

Cardiac Disease and Peripartum Cardiomyopathy

Cardiovascular conditions are a leading cause of pregnancy-related death. Normal pregnancy brings mild dyspnea, a systolic flow murmur, and dependent edema, but orthopnea, paroxysmal nocturnal dyspnea, chest pain, syncope, resting tachycardia, or oxygen saturation below 95% are red flags. Women with known heart disease are risk-stratified with the modified WHO classification and need cardio-obstetric care.

Peripartum cardiomyopathy: Heart failure with a left ventricular ejection fraction below 45% developing toward the end of pregnancy or in the months after delivery, with no other cause. Risk factors include Black race, preeclampsia or hypertension, multiple gestation, and older age . Evaluate with BNP and echocardiography. Treatment uses diuretics, beta-blockers, and hydralazine with nitrates during pregnancy (ACE inhibitors and ARBs only postpartum), plus anticoagulation for severely reduced function. Recurrence and mortality risks in a later pregnancy are high, especially if heart function has not recovered.